Press Releases | BioLineRx

Date	Title	Additional Formats
31 Aug 2026	BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update	PDF Version
28 Aug 2026	BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement	PDF Version
25 Aug 2026	BioLineRx to Report Second Quarter 2026 Results on August 31, 2026	PDF Version
20 Jul 2026	BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026	PDF Version
08 Jul 2026	BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model	PDF Version
27 May 2026	BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update	PDF Version
22 May 2026	BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting	PDF Version
20 May 2026	BioLineRx to Report First Quarter 2026 Results on May 27, 2026	PDF Version
19 May 2026	BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts	PDF Version
28 Apr 2026	BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)	PDF Version
26 Mar 2026	BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)	PDF Version
23 Mar 2026	BioLineRx Reports 2025 Financial Results and Provides Corporate Update	PDF Version
16 Mar 2026	BioLineRx to Report 2025 Annual Results on March 23, 2026	PDF Version